4Terada M.Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells[J].Bone,1998,22(1):17.
5Gori F,Hofbauer LC,Dunstan CR,et al.The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated[J].Endocrinology,2000,141:4768-4776.
6Lam J,Nelson CA,Ross FP,et al.Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity[J].J Clin Invest,2001,108:971-997.
7Grimaud E.Osteoprotegerin:a new agent for the treatment of bone disease[J].Drug Discov Today,2002,6:1241-1242.
8Fazzalari NL,Kuliwaba JS,Atkins GJ,et al.The ratio of messenger RNA levels of receptor activator of nuclear factor kappa B ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis[J].J Bone Miner Res,2001,16:1015-1027.
10Kong YY,Yoshida H,Sarosi I,et al.OPGL is a key regulator of osteoclastogenesis,lymphocyte development and lymph-node organogenesis[J].Nature,1999,397:315-323.
